drugset / Trial / NCT04859569
Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter，randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone metastases from solid tumors.
Timeline
- Start
- 2021-04-30
- Primary completion
- 2022-12-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | LY01011 | Monoclonal antibody | 120 mg | Subcutaneous |